Michael R Dwyer

US Patent:

6919341, Jul 19, 2005

Filed:

Sep 19, 2003

Appl. No.:

10/665005

Inventors:

Kamil Paruch - Garwood NJ, US
Timothy J. Guzi - Chatham NJ, US
Michael P. Dwyer - Scotch Plains NJ, US
Ronald J. Doll - Convent Station NJ, US
Viyyoor M. Girijavallabhan - Parsippany NJ, US
Alan Mallams - Hackettstwon NJ, US

Assignee:

Schering Corporation - Kenilworth NJ

International Classification:

C07D487/04
A61K031/495

US Classification:

514249, 544350

Abstract:

In its many embodiments, the present invention provides a novel class of imidazo[1,2-a]pyrazine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.

US Patent:

6992080, Jan 31, 2006

Filed:

Sep 17, 2003

Appl. No.:

10/664338

Inventors:

Michael P. Dwyer - Scotch Plains NJ, US
Timothy J. Guzi - Chatham NJ, US
Kamil Paruch - Garwood NJ, US
Ronald J. Doll - Convent Station NJ, US
Kartik M. Keertikar - East Windsor NJ, US
Viyyoor M. Girijavallabhan - Parsippany NJ, US

Assignee:

Schering Corporation - Kenilworth NJ

International Classification:

A61K 31/435
A61K 31/505
A61K 31/44
C07D 471/02
C07D 401/14

US Classification:

51421707, 514303, 514300, 51425304, 514256, 544362, 544333, 546121, 546113

Abstract:

In its many embodiments, the present invention provides a novel class of imidazo[1,2-a]pyridine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.

US Patent:

7151104, Dec 19, 2006

Filed:

Sep 17, 2003

Appl. No.:

10/664337

Inventors:

Michael P. Dwyer - Scotch Plains NJ, US
Timothy J. Guzi - Chatham NJ, US
Kamil Paruch - Garwood NJ, US
Ronald J. Doll - Convent Station NJ, US
Kartik M. Keertikar - East Windsor NJ, US
Viyyoor M. Girijavallabhan - Parsippany NJ, US

Assignee:

Schering Corporation - Kenilworth NJ

International Classification:

C07D 271/00
C07D 221/02
A01N 43/90

US Classification:

5142591, 514359, 546112, 546113, 546119, 546121, 548100, 548125, 548126

Abstract:

In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyridine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.

US Patent:

7186740, Mar 6, 2007

Filed:

Sep 19, 2003

Appl. No.:

10/666424

Inventors:

Kamil Paruch - Garwood NJ, US
Timothy J. Guzi - Chatham NJ, US
Michael P. Dwyer - Scotch Plains NJ, US
Ronald J. Doll - Convent Station NJ, US
Viyyoor M. Girijavallabhan - Parsippany NJ, US

Assignee:

Schering Corporation - Kenilworth NJ

International Classification:

A01N 43/50
C07D 403/02
C07D 235/02

US Classification:

514396, 514359, 514385, 514393, 5483001, 5483027, 5483031

Abstract:

In its many embodiments, the present invention provides a novel class of imidazo[1,2-a] pyrazine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.

US Patent:

7432265, Oct 7, 2008

Filed:

Jan 31, 2005

Appl. No.:

11/047524

Inventors:

Kamil Paruch - Garwood NJ, US
Timothy J. Guzi - Chatham NJ, US
Michael P. Dwyer - Scotch Plains NJ, US
Ronald J. Doll - Convent Station NJ, US
Viyyoor M. Girijavallabhan - Parsippany NJ, US
Alan Mallams - Hackettstown NJ, US

Assignee:

Schering Corporation - Kenilworth NJ

International Classification:

C07D 487/04
A61K 31/495

US Classification:

514249, 544350

Abstract:

In its many embodiments, the present invention provides a novel class of imidazo[1,2-a]pyrazine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.

US Patent:

7449488, Nov 11, 2008

Filed:

Oct 6, 2005

Appl. No.:

11/244628

Inventors:

Kamil Paruch - Garwood NJ, US
Timothy J. Guzi - Chatham NJ, US
Michael P. Dwyer - Scotch Plains NJ, US

Assignee:

Schering Corporation - Kenilworth NJ

International Classification:

C07D 231/00
C07D 231/54
A61K 31/415
A01N 43/56

US Classification:

514405, 514403, 514514, 514406, 546 1, 546 26, 546112, 546134, 5483561, 5483581, 5483601

Abstract:

In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of protein and/or checkpoint kinases, methods of preparing such compounds, pharmaceutical compositions including one or more such compounds, methods of preparing pharmaceutical formulations including one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the protein or checkpoint kinases using such compounds or pharmaceutical compositions. The invention also relates to the inhibition of hepatitis C virus (HCV) replication. In particular, embodiments of the invention provide compounds and methods for inhibiting HCV RNA-dependent RNA polymerase enzymatic activity. The invention also provides compositions and methods for the prophylaxis and treatment of HCV infection.

US Patent:

7452902, Nov 18, 2008

Filed:

Sep 29, 2005

Appl. No.:

11/238597

Inventors:

Michael P. Dwyer - Scotch Plains NJ, US
Timothy J. Guzi - Chatham NJ, US
Kamil Paruch - Garwood NJ, US
Ronald J. Doll - Convent Station NJ, US
Kartik M. Keertikar - East Windsor NJ, US
Viyyoor M. Girijavallabhan - Parsippany NJ, US

Assignee:

Schering Corporation - Kenilworth NJ

International Classification:

A01N 43/42
A61K 31/44

US Classification:

514300

Abstract:

In its many embodiments, the present invention provides a novel class of imidazo[1,2-a]pyridine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.

US Patent:

7645762, Jan 12, 2010

Filed:

Oct 4, 2006

Appl. No.:

11/542902

Inventors:

Kamil Paruch - Garwood NJ, US
Timothy J. Guzi - Chatham NJ, US
Michael P. Dwyer - Scotch Plains NJ, US

Assignee:

Schering Corporation - Kenilworth NJ

International Classification:

C07D 487/04
A61K 31/519
A61P 35/04

US Classification:

5142593, 544281

Abstract:

In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of protein and/or checkpoint kinases, methods of preparing such compounds, pharmaceutical compositions including one or more such compounds, methods of preparing pharmaceutical formulations including one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the protein or checkpoint kinases using such compounds or pharmaceutical compositions. An illustrative compound is shown below:.